S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
NASDAQ:GLPG

Galapagos Stock Forecast, Price & News

$48.29
-0.29 (-0.60%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$48.24
$49.76
50-Day Range
$48.24
$57.12
52-Week Range
$47.80
$125.85
Volume
189,195 shs
Average Volume
279,311 shs
Market Capitalization
$3.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.58
30 days | 90 days | 365 days | Advanced Chart
Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.


Galapagos logo

About Galapagos

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Headlines

Galapagos (NASDAQ:GLPG) Hits New 1-Year Low at $47.82
November 30, 2021 |  americanbankingnews.com
Galapagos (NASDAQ:GLPG) Reaches New 1-Year Low at $47.96
November 23, 2021 |  americanbankingnews.com
Galapagos (NASDAQ:GLPG) Shares Gap Down to $52.30
November 17, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLPG
Employees
1,304
Year Founded
N/A

Sales & Book Value

Annual Sales
$605.66 million
Book Value
$46.63 per share

Profitability

Net Income
$-348.90 million
Pretax Margin
-41.96%

Debt

Price-To-Earnings

Miscellaneous

Free Float
63,623,000
Market Cap
$3.16 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/05/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/24/2022

MarketRank

Overall MarketRank

1.52 out of 5 stars

Medical Sector

1062nd out of 1,392 stocks

Pharmaceutical Preparations Industry

502nd out of 669 stocks

Analyst Opinion: 3.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Galapagos (NASDAQ:GLPG) Frequently Asked Questions

Is Galapagos a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Galapagos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View analyst ratings for Galapagos
or view top-rated stocks.

How has Galapagos' stock price been impacted by COVID-19 (Coronavirus)?

Galapagos' stock was trading at $186.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GLPG shares have decreased by 74.0% and is now trading at $48.29.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Galapagos?

Galapagos saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 563,400 shares, an increase of 52.5% from the October 31st total of 369,500 shares. Based on an average trading volume of 238,200 shares, the short-interest ratio is currently 2.4 days. Approximately 0.9% of the shares of the stock are sold short.
View Galapagos' Short Interest
.

When is Galapagos' next earnings date?

Galapagos is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Galapagos
.

How were Galapagos' earnings last quarter?

Galapagos NV (NASDAQ:GLPG) posted its earnings results on Friday, November, 5th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.67) by $0.50. The biotechnology company earned $75.69 million during the quarter, compared to analyst estimates of $95.17 million. Galapagos had a negative trailing twelve-month return on equity of 7.81% and a negative net margin of 36.28%.
View Galapagos' earnings history
.

What price target have analysts set for GLPG?

12 brokerages have issued 12 month target prices for Galapagos' shares. Their forecasts range from $50.00 to $170.00. On average, they anticipate Galapagos' stock price to reach $98.26 in the next twelve months. This suggests a possible upside of 103.5% from the stock's current price.
View analysts' price targets for Galapagos
or view top-rated stocks among Wall Street analysts.

Who are Galapagos' key executives?

Galapagos' management team includes the following people:
  • Onno van de Stolpe, Chief Executive Officer
  • Bart Filius, President & Chief Operating Officer
  • Piet Wigerinck, Chief Scientific Officer
  • Walid Abi-Saab, Chief Medical Officer
  • Andre Hoekema, Chief Business Officer

What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos CEO Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among Galapagos' employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

When did Galapagos IPO?

(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Who are Galapagos' major shareholders?

Galapagos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include EcoR1 Capital LLC (2.38%), BVF Inc. IL (1.71%), 683 Capital Management LLC (1.07%), BlackRock Inc. (0.59%), Stonepine Capital Management LLC (0.37%) and Millennium Management LLC (0.32%).

Which institutional investors are selling Galapagos stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Caption Management LLC, Morgan Stanley, BlackRock Inc., Advisor Group Holdings Inc., Jane Street Group LLC, UBS Group AG, and Citigroup Inc..

Which institutional investors are buying Galapagos stock?

GLPG stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, BVF Inc. IL, 683 Capital Management LLC, Stonepine Capital Management LLC, Millennium Management LLC, HAP Trading LLC, Renaissance Technologies LLC, and Hudson Bay Capital Management LP.

How do I buy shares of Galapagos?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galapagos' stock price today?

One share of GLPG stock can currently be purchased for approximately $48.29.

How much money does Galapagos make?

Galapagos has a market capitalization of $3.16 billion and generates $605.66 million in revenue each year.

How many employees does Galapagos have?

Galapagos employs 1,304 workers across the globe.

What is Galapagos' official website?

The official website for Galapagos is www.glpg.com.

Where are Galapagos' headquarters?

Galapagos is headquartered at GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at (321) 534-2900, via email at [email protected], or via fax at 321-534-2901.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.